Study of TRIFLURIDINE/TIPIRACIL in Previously Treated Cholangiocarcinoma

NCT04076761 | Terminated Phase 2

• 1 other identifier: CTO 1645
• Study Type: interventional
• Target: 8
• Locations: 1 country
• Sites: 1

Brief Summary

This is a multi-centre, open-label, single arm phase 2 study to assess the efficacy of TRIFLURIDINE/TIPIRACIL, in patients with advanced cholangiocarcinoma as measured by median progression-free survival (PFS). This study will enroll a total of 47 patients over a 12-month period, according to a two stage enrollment design. Nine patients will be enrolled during the first stage and the trial will be terminated if 4 or more out of the 9 have disease progression. If the trial goes on to the second stage, a total of 47 patients (38 in second stage) will be required. Patients will be seen prior to enrolment (within 28 days of treatment), every 4 weeks while on treatment, at the end of treatment, and 30 days post-treatment. Patients will remain on long-term follow-up and will be seen every 12 weeks (+/- 14 days) until 1 year post-treatment when they will enter into the survival follow-up period and will be contacted every 12 weeks by phone until progression or toxicity.

Conditions

Cholangiocarcinoma; Bile Duct Cancer

Keywords

Cholangiocarcinoma; Bile Duct Cancer; FTD/TPI; TRIFLURIDINE/TIPIRACIL

Outcome Measures

Primary Outcomes (1)

• Median progression-free survival (PFS)

  As measured on the basis of RECIST v1.1 criteria

  From enrolment until the date of objective radiological disease progression according to RECIST v1.1 or death (by any cause in the absence of progression) up to 1 year

Secondary Outcomes (5)

• Safety and tolerability of FTD/TPI: CTCAE version 5.0

  Day 1 of each new treatment cycle (each cycle is 28 days), and at the end of treatment visit (up to 1 year after enrolment)

• Disease Control Rate (Complete Response, Partial Response, Stable Disease) of FTD/TPI

  From enrolment until the date of objective radiological disease progression according to RECIST v1.1 or death (by any cause in the absence of progression) up to 1 year

• Duration of response of FTD/TPI

  From enrolment until the date of objective radiological disease progression according to RECIST v1.1 or death (by any cause in the absence of progression) up to 1 year

• Median overall survival of patients with cholangiocarcinoma treated with FTD/TPI.

  From enrolment until the date of objective radiological disease progression according to RECIST v1.1 or death (by any cause in the absence of progression) up to 1 year

• Quality of life: European Organisation for Research and Treatment of Cancer Quality-of-life Questionnaire Core 30

  Baseline, and Day 1 of each new treatment cycle (each cycle is 28 days), and at the end of treatment visit (up to 1 year after enrolment)

Study Arms (1)

Trifluridine/Tipiracil

EXPERIMENTAL

FTD/TPI at 35 mg/m2 (based on BSA) that is administered in tablet form, orally, twice daily, within one hour of morning and evening meals, on days 1-5 and days 8-12 of a 28 day cycle.

Drug: Trifluridine/Tipiracil

Interventions

Trifluridine/Tipiracil DRUG

FTD/TPI is an orally administered combination of a thymidine-based nucleic acid analogue, trifluridine, and a thymidine phosphorylase inhibitor, tipiracil hydrochloride. Trifluridine is the active cytotoxic component of FTD/TPI; its triphosphate form is incorporated into DNA, with such incorporation appearing to result in its anti- tumor effects. Tipiracil hydrochloride is a potent inhibitor of thymidine phosphorylase and, when combined with trifluridine to form FTD/TPI, prevents the rapid degradation of the trifluridine, allowing for the maintenance of adequate plasma levels of the active drug.

Also known as: FTD/TPI, Lonsurf

Trifluridine/Tipiracil

Eligibility Criteria

• Age: 18 Years+
• Sex: all
• Healthy Volunteers: No
• Age Groups: Adult (18-64), Older Adult (65+)

You may qualify if:

• Histologically documented locally advanced or metastatic biliary tract cancer (intra or extrahepatic cholangiocarcinoma or gallbladder cancer) previously treated with first line standard chemotherapy (gemcitabine-based chemotherapy at least one cycle). Patients who develop a recurrence after adjuvant capecitabine therapy must have subsequently received at least one cycle of a gemcitabine-based therapy to be eligible. Patients who have received gemcitabine in the adjuvant setting but progressed within 6 months of their last cycle will be eligible for the study.
• Presence of measurable disease as assessed by CT scan of the chest, abdomen and pelvis based on RECIST 1.1.
• ECOG performance status of 0 or 1.
• Expected life expectancy of ≥ 3 months.
• Age 18 years and above
• Able to swallow and retain oral medication.
• Adequate hematologic function defined by the following laboratory parameter:
• Hemoglobin ≥ 9g/dL
• Absolute neutrophil count ≥1.5 x 109/L
• Platelet count ≥75x 109/L
• Adequate hepatic and renal function as defined by:
• AST and ALT ≤ 3.0 X ULN (≤ 5 if liver metastasis present)
• Total bilirubin ≤ 1.5X ULN
• Calculated creatinine clearance ≥50 ml/min using Cockcroft-Gault formula
• Patients who have treated brain metastasis (via local radiation standards or surgical resection or local techniques) and who are either off steroids or on a stable dose of steroids for at least one month (30 days), AND who are off anticonvulsants, AND have radiological documented stability of lesions for at least 3 months may be eligible.

You may not qualify if:

• Any malignancy related to HIV, history of HIV, history of known HBV surface antigen positivity (subjects with documented laboratory evidence of HBV clearance may be enrolled) or positive HCV antibody. Testing for these diseases is not mandatory unless clinically indicated
• Chemotherapy, radiotherapy, immunotherapy, or other anti-cancer therapy including investigational drugs within 28 days prior to enrolment.
• Patients with unresolved Grade 3/4 toxicities from prior therapies.
• Any major surgery within the last four weeks.
• Previous or concurrent malignancies, excluding curatively treated in situ carcinoma of the cervix or uterus or non-melanoma skin cancer or in-situ carcinoma of the prostate (Gleason score ≤ 7, with all treatment being completed 6 months prior to enrollment, unless at least 5 years have elapsed since last treatment and the patient is considered cured)
• Patients with locally or centrally known FGFR2 fusion (Sunnybrook, Ottawa and PMCC sites only).
• Female patients of childbearing potential and men able to father children who do not agree to use adequate methods of contraception from time of enrolment until 6 months after the last date of treatment administration.
• Women who are breastfeeding
• Patients with suspected or documented leptomeningeal disease.

Sponsors & Collaborators

• Sunnybrook Health Sciences Centre: lead
• Taiho Oncology, Inc.: collaborator

Study Sites (1)

Sunnybrook Health Sciences Centre

Toronto, Ontario, M4N 3M5, Canada

Location

MeSH Terms

Conditions

Cholangiocarcinoma; Bile Duct Neoplasms

Interventions

trifluridine tipiracil drug combination

Condition Hierarchy (Ancestors)

Adenocarcinoma; Carcinoma; Neoplasms, Glandular and Epithelial; Neoplasms by Histologic Type; Neoplasms; Biliary Tract Neoplasms; Digestive System Neoplasms; Neoplasms by Site; Bile Duct Diseases; Biliary Tract Diseases; Digestive System Diseases

Study Design

• Study Type: interventional
• Phase: phase 2
• Allocation: NA
• Masking: NONE
• Purpose: TREATMENT
• Intervention Model: SINGLE GROUP
• Sponsor Type: OTHER
• Responsible Party: SPONSOR

Study Record Dates

• First Submitted: August 22, 2019
• First Posted: September 3, 2019
• Study Start: December 11, 2019
• Primary Completion: September 30, 2022
• Study Completion: September 30, 2022
• Last Updated: December 1, 2022

Record last verified: 2022-11

Locations

CA (1)